Market revenue in 2023 | USD 622.7 million |
Market revenue in 2030 | USD 1,313.0 million |
Growth rate | 11.2% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.47% in 2023. Horizon Databook has segmented the Norway precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
In December 2021, Illumina, Inc. announced that it would be supporting Norway’s precision medicine study to evaluate blood-based Comprehensive Genomic Profiling (CGP) efficiency in the selection of cancer therapy. The study would also evaluate the cost-effectiveness of blood-based CGP implementation in the healthcare system.
Tissue sampling could be replaced with less invasive CGP testing on blood samples, thus expanding the number of people whose tumors can be profiled and who can then be enrolled in clinical trials for cancer therapy selection. Norway has established a network of drug information centers, Regionale legemiddelinformasjonssentre (RELIS).
This service promotes access to personalized medicine in the country. In October 2020, the government of Norway increased the budget for personalized medicine in its newly released state budget. The budget was increased to a total of USD 5.69 million (NOK 61.3 million). This increased budget is intended to be used to improve molecular diagnostics capabilities in hospitals to increase the adoption of precision medicine.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into Norway precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account